Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuroendocrine Tumors
Conditions
Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
Trial Timeline
Jul 17, 2023 → Mar 31, 2028
NCT ID
NCT05746208About Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate is a phase 2 stage product being developed by Merck for Neuroendocrine Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05746208. Target conditions include Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05746208 | Phase 2 | Recruiting |
Competing Products
20 competing products in Neuroendocrine Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-α-NET + [212Pb]VMT-α-NET | Perspective Therapeutics | Phase 1/2 | 33 |
| [203Pb]VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| [212Pb] VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Olaparib | AstraZeneca | Phase 2 | 52 |
| Avelumab | Merck | Phase 1/2 | 41 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab Injection | Merck | Phase 2 | 52 |
| Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab | Merck | Phase 1 | 33 |
| Avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Lenvatinib | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Irinotecan + Paclitaxel | Merck | Phase 2 | 52 |
| MK-0646 | Merck | Phase 2 | 52 |
| Lanreotide + Pembrolizumab | Merck | Phase 1/2 | 41 |